# A Safety and Efficacy Study to Evaluate Rosacea

> **NCT03883945** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **AiViva BioPharma, Inc.**

## Conditions studied

- Papulopustular Rosacea

## Interventions

- **DRUG:** AIV001
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT03883945
- **Lead sponsor:** AiViva BioPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07
- **Primary completion:** 2022-07
- **Final completion:** 2022-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor deprioritization
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03883945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03883945, "A Safety and Efficacy Study to Evaluate Rosacea". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03883945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*